Abstract
Introduction: Tenofovir disoproxil fumarate (TDF) is active against lamivudine resistant hepatitis B virus (HBV). Response to TDF treatment in a subset of patients from the phase 3, studies 102 (HBeAg-negative patients) and 103 (HBeAg-positive patients) previously treated for >12 weeks with lamivudine or emtricitabine (LAM-experienced) was compared to LAM-naïve patients in these two studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
